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Introduction: Extracellular ATP (eATP) is released by articular chondrocytes under physiological and pathological
conditions. High eATP levels cause pathologic calcification, damage cartilage, and mediate pain. We recently
showed that stable over-expression of the progressive ankylosis gene product, ANK, increased chondrocyte eATP
levels, but the mechanisms of this effect remained unexplored. The purpose of this work was to further investigate
mechanisms of eATP efflux in primary articular chondrocytes and to better define the role of ANK in this process.
Methods: We measured eATP levels using a bioluminescence-based assay in adult porcine articular chondrocyte
media with or without a 10 minute exposure to hypotonic stress. siRNAs for known ATP membrane transporters
and pharmacologic inhibitors of ATP egress pathways were used to identify participants involved in chondrocyte
eATP release.
Results: eATP levels increased after exposure to hypotonic media in a calcium-dependent manner in monolayer
and 3-dimensional agarose gel cultures (p < 0.001). A potent transient receptor potential vanilloid 4 (TRPV4) agonist
mimicked the effects of hypotonic media. ANK siRNA suppressed basal (p < 0.01) and hypotonically-stressed (p < 0.001)
ATP levels. This effect was not mediated by altered extracellular pyrophosphate (ePPi) levels, and was mimicked by the
ANK inhibitor, probenecid (p < 0.001). The P2X7/4 receptor inhibitor Brilliant Blue G also suppressed eATP efflux
induced by hypotonic media (p < 0.001), while ivermectin, a P2X4 receptor stimulant, increased eATP levels (p < 0.001).
Pharmacologic inhibitors of hemichannels, maxianion channels and other volume-sensitive eATP efflux pathways did
not suppress eATP levels.
Conclusions: These findings implicate ANK and P2X7/4 receptors in chondrocyte eATP efflux. Understanding the
mechanisms of eATP efflux may result in novel therapies for calcium crystal arthritis and osteoarthritis.Introduction
ATP is a key energy-storing compound found in milli-
molar concentrations inside healthy cells [1]. Most cell
types release ATP to the extracellular space under both
physiologic and pathologic conditions [1]. In articular
cartilage, low levels of extracellular ATP (eATP) trans-
duce mechanical signals [2]. Higher levels of eATP pro-
duce pathologic calcium crystal formation such as that* Correspondence: ann.rosenthal@va.gov
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reproduction in any medium, provided the orseen with calcium pyrophosphate (CPP) and basic cal-
cium phosphate (BCP) crystal deposition in cartilage [3].
eATP also induces production of catabolic mediators
such as prostaglandins [4], and activates nociceptive re-
ceptors inducing pain [5]. Some of these effects are me-
diated through purinergic receptors. However, as eATP
belongs to the danger-associated molecular pattern
(DAMP) family of innate immune signals, it may also con-
tribute to cartilage damage through this mechanism [6,7].
While processes that regulate ATP efflux may be logical
therapeutic targets in common degenerative cartilage dis-
eases, surprisingly little is known about transport mecha-
nisms of ATP across the chondrocyte cell membrane.ral Ltd. This is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Rosenthal et al. Arthritis Research & Therapy 2013, 15:R154 Page 2 of 12
http://arthritis-research.com/content/15/5/R154We recently showed that stable over-expression of the
progressive ankylosis gene product (ANK) dramatically
increases eATP levels in articular chondrocytes [8]. ANK
is a 492 amino acid multipass transmembrane protein
originally described as the mutated protein in ank/ank
mice [9]. Considerable evidence supports its role in
extracellular pyrophosphate (ePPi) transport [9,10]. ePPi
is a key regulator of pathologic mineralization in cartil-
age and other tissues. ePPi can be generated from eATP
through the action of ecto-enzymes with nucleoside tri-
phosphate pyrophosphohydrolase (NTPPPH) activity,
such as ENPP1. Because there is ample ENPP1 activity
in normal cartilage to convert all available NTP to NMP
and PPi, substrate availability is the rate-limiting step in
this reaction [11]. We recently demonstrated that chon-
drocyte eATP and ePPi elaboration were coordinately
regulated [8], supporting a major role for eATP in ePPi
production by cartilage. Thus, delineating mechanisms
of eATP efflux in cartilage may lead to the identification
of novel modulators of ePPi production.
Whether ANK itself may act as an ATP transporter in
chondrocytes is not known. Our initial studies involved
stable over-expression of ANK, but did not investigate
whether over-expression could indirectly increase ATP
efflux, for example, by altering the chondrocyte phenotype
or affecting levels of eATP metabolizing ecto-enzymes.
Structural studies of ANK protein make it unlikely that
ANK itself, at least in its monomeric form, is capable of
providing a channel of adequate size to accommodate
ATP (unpublished observation, C. J. Williams). Thus, the
possibility that ANK regulates a known mechanism of cel-
lular ATP export warrants investigation.
Four classic ATP membrane transport mechanisms have
been described to date [1]. Hemichannels, composed of ei-
ther connexin or pannexin proteins, mediate ATP release
in many cell types and have been implicated in chondro-
cyte ATP efflux [12]. Vesicular transport of ATP is best
characterized in nerve cells, where ATP is packaged along
with other neurotransmitters for rapid release upon cell
activation [13]. Vesicular transport of ATP has also been
observed in osteoblasts [14]. Two types of molecularly
undefined ATP transport channels also exist. Maxianion
channels are typically identified by patch clamp experi-
ments, and can be inhibited by anion transport inhib-
itors and gadolinium [15]. Volume-sensitive outwardly
rectifying anion channels (VSOR) or volume-sensitive
organic osmolyte and anion channels (VSOAC) are widely
expressed channels that rapidly develop after cell swelling.
While pharmacologic inhibitors are often used to differen-
tiate between various ATP release mechanisms, interpre-
tations of inhibitor experiments are complicated by
considerable overlap in the actions of these agents and
anomalous inhibitor responses when multiple transport
mechanisms are present in one cell type [1,16].The ionotropic P2X purinergic receptors, P2X7 and
P2X4, have also been implicated in eATP release [17].
These complex receptors respond to stimuli by rapidly
opening cation channels and initiating cell signaling. In
many cell types, P2X7 and P2X4 receptor channels also
comprise or regulate pores capable of transporting mole-
cules as large as 900 Da [18]. P2X7 may co-localize with
pannexin proteins, and in some cases hemichannel in-
hibitors block the activity of the P2X7-regulated large
pore [16,19]. P2X7 homotrimeric channels can directly
interact with P2X4 homotrimeric channels with conse-
quent changes in trafficking and function of these receptors
[20]. Whether purine receptors participate in chondrocyte
ATP efflux is not fully understood.
ATP release in cartilage is modulated by mechanical
stimuli such as tissue compression and by changes in os-
motic pressure. These stimuli are linked by similar ef-
fects on membrane tension, and often share signaling
pathways [21]. Membrane proteins such as the transient
receptor potential vanilloid 4 (TRPV4) may participate
in the response to these stimuli [22]. Several studies
demonstrate increased ATP efflux in chondrocytes sub-
jected to mechanical compression [12,23]. Exposure to
osmotic stress is a commonly used model to study ATP
efflux [24,25]. Osmotic changes are particularly relevant
in cartilage, where mechanical forces repetitively force
water in and out of the highly charged extracellular matrix.
Normal chondrocytes reside in a hyperosmolar environ-
ment (350 to 480 mOsm/L), which is reduced in well-
established osteoarthritis (OA) to 280 to 350 mOsm/L
[26,27]. The effects of an osmotic challenge on eATP re-
lease in articular chondrocytes and the signals involved in
this process remain poorly characterized.
The purpose of this work was to further identify
mechanisms of basal and hypotonically stressed eATP
efflux in primary articular chondrocytes and characterize
the involvement of ANK in these processes.
Methods
Materials
Unless otherwise specified, all reagents were from Sigma
Aldrich Chemical Co. (St Louis, MO, USA): 10panx1 and
its scramble control, the P2X7 inhibitors A438079 and
AZ10606120, and GSK1016790A, were obtained from
Tocris (Ellisville, MO, USA).
Chondrocyte cultures
Primary hyaline articular chondrocytes were isolated
from knee joints of 3- to 5-year-old pigs as previously
described [28]. Knee cartilage was obtained from pigs
slaughtered at a local abattoir and was used in accord-
ance with guidelines from the Subcommittee on Animal
Use of the Research and Development Committee of the
Zablocki VA Medical Center. Chondrocytes were plated
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within 3 days of plating. DMEM (low glucose, 335 ± 30
mOsm/L) was used for all experiments. Initial experi-
ments were repeated with chondrocytes embedded in
2% agarose constructs. To embed chondrocytes, freshly
digested cells (5 × 106 cells/ml) were mixed 1:1 with 4%
agarose in Hank’s Balanced Salt Solution (HBSS). One
hundred μl of warm agarose containing cells were added
to each well of a 96-well plate and allowed to solidify.
After solidification, 150 μl of DMEM were added to each
well.
eATP measurements
Media were removed from chondrocytes plated in 96-
well clear-bottom black plates, and replaced with fresh
serum-free DMEM with or without ATP modulators or
other additives. After 30 minutes aliquots of media were
removed and replaced with an equal volume of sterile
water to expose cells to hypotonic media or fresh DMEM
as a control. After 10 minutes eATP levels were measured
in the media using the Sigma ATP Assay Mix (FLAAM)
and read in a BioTek® Synergy HT plate reader (BioTek®,
Winooski, VT, USA). The osmolarities of all media prepa-
rations including those with and without inhibitors and
other additives were measured with an Osmette osmom-
eter (Precision Systems, Natick, MA, USA). Media osmo-
larities were as follows: undiluted media 362 to 302
mOsm/L, 15% H2O 282 to 249 mOsm/L, 35% H2O 216 to
192 mOsm/L, and 50% H2O 166 to 143 mOsm/L. No
media additives, except for water, altered media osmolarity
more than 10% (data not shown). We chose to use 10 to
50% water as an osmotic challenge, as this level of osmotic
stress typically induces eATP release in other cell types
[29,30]. Each culture additive and osmotic condition was
tested for effects on the ATP standard curve. If effects
were noted, as they were in the case of sodium pyrophos-
phate (NaPPi) and Brilliant Blue G (BBG), calculated ATP
levels were adjusted accordingly.
ATP metabolizing ecto-enzyme activities
Specific activities of the ecto-enzymes that metabolize
ATP were measured, as changes in these enzyme activities
could affect eATP levels without altering transport.
NTPPPH activity was measured using 2 mM p-nitrophenol
thymidine monophosphate (PNPMP) as a substrate. Briefly,
the media were removed and replaced with PNPMP in
HBSS. The cells were incubated for 2 h at 37°C and the
reaction was stopped with the addition of 0.1 N NaOH.
The absorbance was measured at 410 nm using a Biotek
plate reader. Activity of the phosphate-generating enzyme,
5′ nucleotidase (5′ NT), was determined with a kit used ac-
cording to manufacturer’s directions (BQ Kits, San Diego,
CA, USA) [31]. Alkaline phosphatase activity was measured
using p-nitrophenol phosphate (PNPP) as a chromogenicsubstrate. Cells were lysed in 0.9% saline with 0.2% Triton™
x-100. Equal volumes of alkaline buffer solution and PNPP
were added and incubated for 15 minutes at 37°C. The re-
action was stopped with 0.05 N NaOH and absorbance was
measured as described above. All results were corrected for
protein levels in the samples using the Lowry assay.
Calcium dependence
To determine if the ATP response to a hypotonic chal-
lenge was calcium dependent, we exposed chondrocytes
to the calcium ionophore, A23187. Bis-N,N,N',N'-tetraa-
cetic acid-AM (BAPTA-AM) was used to buffer changes
in intracellular calcium flux as described [32,33]. We also
explored the ability of the TRPV4 agonist GSK1016790A
to stimulate eATP efflux.
Cell toxicity
All culture additives were tested for toxicity using the 3-
(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium brom-
ide (MTT) formazan assay according to manufacturer’s
directions.
Chondrocyte transfection
Chondrocytes freshly isolated from whole cartilage were
nucleofected with siRNA for the protein of interest or
non-targeting scramble control with an Amaxa Nucleo-
fection device using program H-020. All silencers were
purchased from Life Technologies (Grand Island, NY,
USA). Stealth silencers for P2X4 and P2X7 were custom
designed using porcine-specific sequences, and ANK si-
lencer (133667) was predesigned and prevalidated. Prior
to plating transfected cells, viability was assessed with
trypan blue. Transfected chondrocytes were incubated in
monolayer cultures for 48 to 72 h prior to RNA isola-
tion, and eATP measurements were performed.
RNA isolation, reverse transcription and real-time PCR
Total RNA was extracted from chondrocytes using the
PureLink Mini RNA kit (Life Technologies). cDNA was
synthesized from 1 μg of total RNA using QuantiTect
Reverse Transcription kit (Qiagen, Valencia, CA, USA),
which includes a genomic DNA elimination step. mRNA
expression was measured by quantitative real-time PCR
using SYBR Green Master I Mix on the LightCycler 480
Real-Time PCR System (Roche, Indianapolis, IN, USA).
Two reference genes were selected for normalization after
determining they were stably expressed across samples.
After verifying similar amplification efficiencies with a 5-
point standard curve, the comparative cycle threshold (Ct)
method was used to calculate fold change. Cycling condi-
tions were set as follows: one cycle at 95°C for 10 minutes,
40 cycles of 95°C for 15 seconds, 60°C for 30 seconds, and
72°C for 15 seconds. A melting curve analysis was per-
formed to confirm amplification specificity. The final PCR
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stained agarose gel to verify the presence of a single band.
Primer sequences are available upon request.
Western blotting
Chondrocyte lysates were loaded onto 10% NuPage®
(Invitrogen, Grand Island, NY, USA) Bis-Tris gels. After
electrophoresis, proteins were blotted onto poly-(vinyli-
dene) difluoride membranes (Life Technologies). Mem-
branes were blocked in a Tris-buffered saline (TBS)-igepal-
5% skim milk buffer for 1 h at room temperature. They
were then exposed to antibodies directed against
connexin-43 (Abcam, Cambridge, MA, USA), pannexin
1 and 3, ANK, P2X4, P2X7 and TRPV4 (Santa Cruz, Santa
Cruz, CA, USA) at 1:1,000 to 10,000 dilution for 1.5 to
24.0 h. After washing, the membranes were exposed to
peroxidase-labeled goat anti-rabbit IgG (H + L) or
rabbit anti-goat for 1 h (1:2,500) (Life Technologies).
Both the primary and secondary antibody exposures
were performed in a TBS-igepal-0.5% skim milk buf-
fer. SuperSignal® West Femto Maximum Sensitivity
Substrate (Pierce, Rockford, IL, USA) was used to visualize
immunoreactive protein bands.
Prostaglandin E2 levels
Prostaglandin E2 levels in chondrocyte media were mea-
sured using Parameter™ Prostaglandin E2 kit (R&D Systems,
Minneapolis, MN, USA) according to manufacturer’s
directions.
Statistics
All experiments were repeated a minimum of three
times. An individual experiment is considered as the
data derived from a chondrocyte culture isolated from
one set of pig knees. The number of replicates (n) within
experiments was typically eight in each group. As ATP
levels failed to satisfy criteria for parametric variables,
the non-parametric Mann–Whitney U-test was used to
determine the statistical significance of the inhibitor
effects on eATP release. Parametric outcomes were eval-
uated with the unpaired Student t-test. Statistical signifi-
cance was set at P <0.05.
Results
eATP levels in chondrocyte media are increased by
exposure to hypotonic conditions, and proteins
implicated in eATP efflux are present in chondrocytes
Baseline eATP levels in chondrocyte-conditioned media
were consistently measureable, but absolute values var-
ied considerably between experiments. Exposure to more
than 35% water significantly increased eATP levels after
10 minutes in a dose-dependent manner as shown in the
representative experiment in Figure 1A (P <0.001). We
demonstrated an identical dose response to a hypotonicchallenge in chondrocytes embedded in an agarose
matrix (P <0.001) (Figure 1B). Levels fell back to baseline
levels 2 h after a hypotonic challenge (Figure 1C). These
findings support the physiologic relevance of the mono-
layer culture system. For all further experiments, mono-
layer cultures were utilized, and exposure to 35% water
for 10 minutes was chosen as the standard hypotonic
challenge. To characterize the potential participants in
eATP efflux in primary chondrocytes, we ensured that
pannexin-1 and −3, connexin 43, ANK, P2X7, and P2X4
were present using western blotting and reverse tran-
scription (RT)-PCR (Figure 1D).
The response to a hypotonic challenge is calcium-dependent
and mimicked by a specific TRPV4 agonist
As shown in Figure 2A, the calcium ionophore A23187
stimulated eATP efflux and mimicked the effects of expos-
ure to hypotonic media (P <0.001). As calcium ionophores
have additional cellular effects, we also investigated the ac-
tions of BAPTA-AM, which buffers intracellular calcium.
BAPTA-AM reduced the effect of the hypotonic challenge
on eATP efflux (P <0.001), supporting a role for calcium
(Figure 2B). BAPTA-AM had no effect on basal levels of
eATP. TRPV4 is an osmotically-sensitive non-selective
cation channel that has been implicated in ATP efflux
in other cell types [34] and is present in chondrocytes
(Figure 2D). Figure 2C shows that the TRPV4 agonist,
GSK1016790A, mimics the effects of a hypotonic chal-
lenge (P <0.001). A role for TRPV4 in mediating the
effects of hypotonicity is further supported by the lack of
response to a hypertonic challenge (Figure 2E), a property
characteristic of TRPV4-mediated effects [22].
ANK siRNA suppressed basal and hypotonically stressed
eATP levels in chondrocyte cultures
We have previously shown that over-expression of the
putative ePPi transporter ANK in chondrocytes resulted
in a 10-fold increase in eATP levels compared to con-
trols transfected with an empty viral vector [8]. To ex-
tend these findings, we explored the effect of specifically
reducing ANK levels on eATP levels in chondrocyte
media. eATP levels were suppressed in chondrocytes
treated with ANK siRNA compared to those treated with
a scramble control (P <0.001) (Figure 3A), without alter-
ations of ecto-enzyme activities or cell viability (data not
shown). ANK mRNA (P <0.01) (Figure 3B) and protein
levels (Figure 3C) were significantly reduced in ANK
siRNA-treated chondrocytes. To ensure that reductions
in eATP in ANK-silenced cells were not indirectly due
to decreases in ePPi levels, we added back 10 to 100 μM
NaPPi to the media of ANK-silenced cells and measured
eATP levels. NaPPi did not alter the pH of the media,
which remained at pH 7.4. As shown in the representa-
tive experiment in Figure 3D, the presence of exogenous
Figure 1 Effect of a hypotonic challenge on eATP levels in media from monolayer and agarose cultures and characterization of
putative ATP transport participants. (A) Normal adult porcine chondrocytes were plated in high-density short-term monolayer cultures. Media
were replaced with fresh media (control) or identical quantities of media containing increasing percentages (volume/volume) of H2O. eATP
levels were measured 10 minutes post-treatment. Bars represent mean ± standard error (A-C). eATP levels were increased by 35 and 50% H20
compared to an undiluted media control (n = 8;***P <0.001). (B) Chondrocytes were embedded in 2% agarose. Media were replaced with fresh
media (control) or identical quantities of media containing increasing percentages (volume/volume) of H2O. eATP levels were measured 10 minutes
after the media change. eATP levels were increased by 35 and 50% H20 compared to undiluted media control (n = 8;
***P <0.001). (C) Chondrocytes
were exposed to hypotonic media (gray bars) or isotonic media (black bars) for various lengths of time and eATP levels were measured. eATP levels
were increased compared to unchallenged control at 10 minutes and 1 h (n = 8;***P <0.001, **P <0.01). D. Chondrocyte protein extracts were run in
western blots using specific antibodies against pannexin 1 and 3, ANK, P2X7 and P2X4. Total RNA was reverse transcribed and analyzed for mRNA for
pannexin 1, ANK, P2X7 and P2X4 as described. The final PCR products were electrophoresed on a 1% ethidium bromide-stained agarose gel. Due to
absence of a sequence for porcine pannexin-3, RT-PCR for pannexin-3 was not performed.
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wards levels seen in the scramble control. However,
there were small increases in eATP levels in the pres-
ence of added ePPi seen across groups, which were not
statistically significant. These data suggest that the re-
duction in eATP seen with ANK silencing is not mediated
by changes in ePPi concentrations. Probenecid, which has
been shown to inhibit ANK-mediated PPi transport
[35], reduced eATP levels in a dose-dependent manner
(P <0.001) (Figure 3E).
ANK may act to directly transport ATP or regulate other
ATP transport mechanisms
We also designed experiments to test for the presence of
classic ATP egress pathways by investigating the effects
of inhibitors of these pathways. None of the pharmaco-
logic inhibitors reduced basal eATP levels with the excep-
tion of probenecid (data not shown). Table 1 summarizes
the effects of these pharmacologic inhibitors on eATPlevels measured after a hypotonic challenge. Results are
expressed as the fold change in eATP levels after a hypo-
tonic challenge in the presence of the inhibitor compared
to the absence of the inhibitor. Despite the expression of
hemichannels, including pannexin-1 and connexin-43, by
chondrocytes at the protein and mRNA levels (Figure 1D),
multiple pharmacological inhibitors known to target
hemichannels failed to suppress osmotically induced
chondrocyte ATP. The effect of 10panx1, a small pep-
tide inhibitor of pannexin-1 hemichannels [36], was
indistinguishable from its control peptide at concen-
trations from 100 to 400 μM. Flufenamic acid (30 to
500 μM) and carbenoxolone (1 to 100 μM) also failed
to significantly suppress hypotonically-induced eATP
production. Small decreases in eATP levels were seen
with vesicular transport inhibitors, including monen-
sin (100 μM) and brefeldin (100 μM), but these failed
to achieve statistical significance. Inhibitors implicated


























































































Figure 2 Roles of Ca2+ signaling and transient receptor potential vanilloid 4 (TRPV4) channels in hypotonically-induced release of eATP
from chondrocytes. For the following experiments, chondrocytes were incubated with each additive for 30 minutes in 100 μl of media with no
additives acting as a control. A hypotonic challenge was initiated by removing 35 μl of media, replacing it with 35 μl of H2O. eATP levels were
measured after 10 minutes. Bars represent mean ± standard error. Under control conditions, a hypotonic challenge consistently increases (eATP).
(A) Chondrocytes were incubated with 100 μM A23187, which increased eATP levels (n = 8; **P <0.01, ***P <0.001). (B) Chondrocytes were
incubated with 10 μM bis-N,N,N',N'-tetraacetic acid-AM (BAPTA-AM), which decreased eATP levels after hypotonic challenge compared to control
without BAPTA-AM (n = 8; ***P <0.001). (C) Chondrocytes were incubated with 100 nM GSK1016790A, which increased eATP levels in the basal
state and after a hypotonic challenge compared to a control without GSK 1016790 (n = 8; ***P <0.001). (D) Chondrocyte protein extracts were run
in western blots with TRPV4 antibody (leftpanel). mRNA for TRPV4 was detected with RT-PCR using a specific primer sequence and electrophoresed on
a 1% ethidium bromide-stained agarose gel ( right panel). (E) Chondrocytes were incubated with control media (black bars) or media containing an
additional 100 mM NaCl (gray bars) for 10 minutes after which eATP levels were measured. A hypertonic challenge did not increase eATP levels
compared to the basal state (n = 8; P >0.05).
Rosenthal et al. Arthritis Research & Therapy 2013, 15:R154 Page 6 of 12
http://arthritis-research.com/content/15/5/R154channels such as gadolinium (50 μM) did not effect-
ively decrease eATP levels in the media from osmot-
ically stressed chondrocytes.
Possible roles for P2X7 and P2X4 receptor channels in
chondrocyte eATP release
The insensitivity of chondrocyte eATP accumulation to
multiple inhibitors that target defined ATP release
mechanisms was surprising. Although many studies with
these inhibitors have been performed in cells that over-
express proteins involved in a single ATP transport
mechanism pathway, ATP transport mechanisms have
been successfully teased out in primary cells using these
methodologies [14]. P2X7 receptors may play a direct
role in eATP release in some cell types, as the large pore
that opens upon P2X7 activation may itself release ATP
[17]. P2X4 may also function in this manner [37]. P2X7
and P2X4 receptor protein and mRNA are expressed in
primary chondrocytes (Figure 1D). Complexes contain-
ing both P2X7 homotrimeric channels and P2X4 homo-
trimeric channels have been characterized in leukocytes
[20,38]. As shown in Table 1, we explored the effects of
three different P2X7 receptor inhibitors on eATP release.BBG, which inhibits both P2X4 and P2X7 receptors, sig-
nificantly suppressed eATP levels after a hypotonic chal-
lenge, whereas two specific P2X7 receptor inhibitors,
A438079 and AZ10606120, failed to do so. No effects on
basal eATP levels were seen with any of these inhibitors
(data not shown). To determine whether this pattern cor-
related with other putative P2X7 receptor-mediated ac-
tions, we measured ATP-induced prostaglandin E2 (PGE2)
release from chondrocytes, which is a P2X receptor-
dependent effect, and may also be associated with pore
formation [39]. Only BBG inhibited PGE2 release by chon-
drocytes (P <0.001) (Figure 4A). Moreover, treatment of
chondrocytes with siRNA that targeted P2X7 receptors
failed to significantly decrease hypotonically-stressed ATP
release (Figure 4B) despite causing decreased levels of
P2X7 receptor protein (Figure 4C) and mRNA (P <0.05)
(Figure 4D). The ability of BBG but not A438079,
AZ10606120, or P2X7 siRNA to attenuate ATP release
suggested involvement of the P2X4 subtype. Among the
P2X receptors, P2X4 receptors characteristically respond
to ivermectin with increased channel gating and activity.
As shown in Figure 5A, ivermectin increased eATP levels
in chondrocytes after a hypotonic challenge (P <0.001).









































































































Figure 3 Role of progressive ankylosis gene product (ANK) in basal and hypotonically stressed eATP release from chondrocytes. For
the following experiments, a hypotonic challenge was initiated by removing 35 μl of media, replacing it with 35 μl of H2O. eATP levels were
measured after 10 minutes. Under control conditions, hypotonic challenge consistently increases eATP. Bars represent mean ± standard error;
n = 8 for all analyses. (A) Chondrocytes were transfected with siRNA for ANK or scramble control. After 48 h, cells were exposed for 10 minutes
to hypotonic (gray bars) or isotonic (black bars) media and eATP levels were measured. siANK suppressed eATP levels under basal and
hypotonically challenged conditions (**P <0.01). (B, C) In parallel cultures at 48 h, mRNA and protein were isolated to assess levels of ANK mRNA
(**P <0.01) and protein. Western blots compared effects on ANK versus actin. (D) Transfected chondrocytes (as described above) were exposed to
media containing no additives (control) or 20 μM PPi in 100 μl of media for 30 minutes with or without hypotonic challenge. The addition of PPi
did not alter eATP levels compared to controls without PPi (P >0.05). (E) Chondrocytes were treated with no additives (control), 1 mM
probenecid, 5 mM probenecid or 10 mM probenecid (as described above). After the hypotonic challenge eATP levels with 1 mM probenecid
were not statistically different from the control (P >0.05): 5 to 10 mM probenecid decreased eATP levels in basal and hypotonically challenged
states (**P <0.01, ***P <0.001).
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P2X4 protein (Figure 5C) and mRNA (P <0.01) (Figure 5D)
in chondrocytes treated with P2X4-siRNA, no differences
were observed in eATP levels in P2X4 silenced cells com-
pared to control cells (Figure 5B). Taken together, these
data suggest a redundant system, in which both P2X4 and
P2X7 must be inhibited for ATP efflux to be affected.Pharmacological inhibitors of ATP efflux do not alter
ATP-metabolizing ecto-enzyme activity levels or decrease
cell viability
eATP levels can be altered by changes in the activities of
the ecto-enzymes that metabolize ATP. Cell damage
may also non-specifically increase eATP levels by allowing
leakage from injured cells. To verify that these possible
effects did not contribute to the action of the pharmaco-
logical inhibitors on eATP, we measured activities of ecto-NTPPPH, 5′NT and alkaline phosphatase in the presence
and absence of inhibitors, and used the MTT assay as a
standard measure of cell injury. None of the inhibitors sig-
nificantly altered levels of enzyme activities (Table 1).
With the exception of flufenamic acid, which was toxic at
concentrations greater than 100 μM, no inhibitors or in-
hibitor combinations significantly decreased cell viability.Discussion
These findings support a major and novel role for ANK
in eATP efflux in articular chondrocytes. While it is un-
clear whether ANK itself acts as an ATP channel or regu-
lates such a channel, we propose that the latter possibility
is more likely based on our additional findings that sug-
gest roles for P2X7/4 receptors in this process. eATP pro-
motes many of the pathogenic processes resulting in
calcium crystal deposition and OA in cartilage. Thus,
Table 1 Effects of pharmacologic ATP transport inhibitors on eATP levels, ATP-metabolizing ecto-enzyme activities,
and cell toxicity in hypotonically stressed chondrocyte cultures
Inhibitor Target Dosage Fold change in ATP P N Alk phos NTPPPH 5’NT Toxicity (fold change)
Probenecid ANK, Hemichannels 5 mM 0.59* 0.004 83 103 ± 2.9 108 ± 6.9 122 ± 24.8 1.31
Monensin Vesicular 100 uM 0.74 0.097 50 103 ± 1.8 109 ± 5.3 120 ± 20.2 1.49
GdCl3 Maxianion 50 uM 0.88 0.309 51 106 ± 6.9 104 ± 2.1 126 ± 11.9 2.21
N-ethylmalemide (NEM) Vesicular 100 uM 0.89 0.947 57 101 ± 3.2 110 ± 3.6 116 ± 19.3 1.68
Brefeldin Vesicular 100 uM 0.88 0.739 60 101 ± 3.2 110 ± 3.6 116 ± 19.3 1.68
Carbeneoxolone (CBX) Hemichannels 5 uM 1.45 0.627 40 103 ± 2.9 109 ± 8.4 109 ± 16.9 3.25
Flufenamic acid (FFA) Hemichannels 30 uM 1.14 0.545 40 98 ± 6.5 118 ± 6.0 108 ± 14.4 1.33
10Panx1 Pannexin-1 100 uM 1.3 0.850 43 105 ± 4.7 137 ± 4.6 115 ± 16.8 1.33
10Panx1 Scramble Pannexin-1 100 uM 1.5 0.256 41 104 ± 6.6 142 ± 8.8 83 ± 10.8 1.27
Brilliant Blue G P2X7, P2X4 50 uM 0.367* 0.001 24 147 ± 5.9 142 ± 7.4 155 ± 32 1.26
A438079 P2X7 300 nm 2 0.042 24 131 ± 4.4 136 ± 5.7 92 ± 21.9 1.25
AZ10606120 P2X7 10 nM 1.2 0.806 24 123 ± 6.9 124 ± 4.6 104 ± 23.6 1.12
Chondrocytes were exposed to control media with and without various pharmacologic ATP pathway inhibitors for 30 minutes. Aliquots of media were removed
and replaced with 35% H20 as described. After 10 minutes, eATP levels were measured in the media. eATP results are expressed as a mean fold change in
osmotically challenged eATP levels over control (no inhibitor) conditions; N = number of replicates pooled from three to five experiments: *statistically
significantly inhibition of ATP levels compared to controls. In parallel cultures, specific activities of ATP metabolizing enzymes - alkaline phosphatase (Alk phos),
nucleoside triphosphate pyrophosphohydrolase (NTPPPH), and 5′ nucleotidase (5' NT) - were measured in the cell layer using standard colorimetric assays.
Results are expressed as percent of specific activity of the control (no inhibitor) conditions (means ± standard error, n=6). Cell toxicity was measured with the
3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay. Results are expressed as a fold increase over control (no inhibitor) conditions. There were


























































































Figure 4 Role of P2X7 receptors in signaling and eATP efflux by chondrocytes. (A) Chondrocytes were treated with no additives (control)
or P2X7 inhibitors (Brilliant Blue G (BBG), AZ10606120 or A438079) for 1 h in the presence of 1 mM ATP. Prostaglandin E2 (PGE2) levels in the
media were measured using the Parameter™ Prostaglandin E2 kit (R&D Systems). Bars represent mean ± standard error. BBG reduced ATP-induced
PGE2 levels (n = 8;
***P <0.001). (B) Chondrocytes were transfected with siRNA for P2X7 or a scrambled control. After 48 h, cells were exposed to
hypotonic media for 10 minutes (gray bars) or isotonic media (black bars) and eATP levels were measured. Bars represent mean ± standard error.
Under control conditions, a hypotonic challenge consistently increases (eATP). No differences in eATP levels were noted in siP2X7-treated
chondrocyte media (n = 8; P >0.05). In parallel cultures at 48 h, protein and mRNA were isolated from scramble or siRNA-treated cells as described and
used to assess levels of P2X7 receptor protein (C) and mRNA (D). mRNA levels of P2X7 were suppressed in siRNA-treated cells (*P <0.05). Western blots
compare the effects of siRNA effects on P2X7 receptor levels versus actin.






















































































Figure 5 Role of P2X4 receptors in signaling and eATP release by chondrocytes. (A) Chondrocytes were treated with no additives (control)
or 10 μM ivermectin in 100 μl of media for 30 minutes: 35 μl of media were removed and replaced with 35 μl of media (black bars) or 35 μl
of H2O (gray bars). eATP levels were measured after 10 minutes. Bars represent mean ± standard error. Under control conditions, a hypotonic
challenge consistently increases (eATP). Ivermectin increased eATP levels after a hypotonic challenge (n = 8: ***P <0.001). (B) Chondrocytes were
transfected with siRNA for P2X4 or a scrambled control. After 48 h, cells were exposed to hypotonic media for 10 minutes (gray bars) or isotonic
media (black bars) and eATP levels were measured. Bars represent mean ± standard error. eATP levels in P2X4 -silenced chondrocyte media were
similar to those in the scramble control media (n = 8; P >0.05). In parallel cultures at 48 h, protein and mRNA were isolated from scramble or
siRNA-treated cells as described and used to assess levels of P2X4 receptor protein (C) and mRNA (D). siRNA for P2X4 decreased P2X4 mRNA
(**P <0.01). Western blots compare effects on P2X4 receptor versus actin.
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may provide insights regarding novel therapies for these
diseases.
As is observed in most cell types, chondrocytes release
a burst of ATP after exposure to hypotonic media. In
chondrocytes, this effect is calcium dependent and is
mimicked by a specific chemical agonist of TRPV4, as is
true in other cell types [34,40]. While further work will
be necessary to conclusively implicate TRPV4 in chon-
drocyte eATP release, TRPV4 levels are altered in OA
chondrocytes, and dysregulation of ATP/PPi efflux could
contribute to the excess calcification seen in OA and in
TRPV4-deficient mice [22].
The potent effects of ANK silencing in reducing eATP
levels confirm and mechanistically extend the important
roles of this protein in cartilage homeostasis and disease.
ANK levels are increased in OA [41] and CPP crystal-
containing cartilage [42], and expression of ANK has
been implicated in maintaining the phenotype of healthy
chondrocytes [43]. ANK levels are increased with
mechanical stimuli in vertebral endplate chondrocytes
[44]. We show here that altering levels of ANK is aneffective way of manipulating eATP levels in chondro-
cyte cultures.
Our studies suggest that ANK directly affects eATP ef-
flux. Suppressing ANK protein levels did not result in
changes in ATP metabolizing ecto-enzymes. Moreover,
the effect of ANK silencing on eATP levels was not me-
diated by changes in ePPi. As alkaline phosphatase is a
marker of the hypertrophic phenotype and levels of alka-
line phosphatase activity were unchanged in ANK-silenced
cells, we have no evidence to suggest that an altered chon-
drocyte phenotype is responsible for the changes in eATP
levels with ANK manipulation.
The drug, probenecid, acts as a potent inhibitor of
both basal and stimulated ATP efflux in chondrocytes.
Probenecid may be directly interacting with ANK, as has
been hypothesized by Ho et al. [9], but may also inhibit
hemichannels. We feel that this is an unlikely mechan-
ism for the probenecid effect as no other hemichannel
inhibitor reduced eATP efflux. Probenecid also functions
as a weak phosphodiesterase inhibitor, but does not ap-
pear to act through this mechanism in chondrocytes
[35]. The actions of organic anion transporters (OATs)
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vations that OATs are downregulated by protein kinase
C (PKc) [45], and that PKc activation increases chondro-
cyte eATP levels [8], argue against a likely role for OATs
in eATP release. Although plasma levels of probenecid
under therapeutic conditions are 10-fold lower than
levels typically used in cell culture [46], this drug has a
long history of safety and efficacy in patients with gout.
While ANK itself may transport ATP, our findings sug-
gest that P2X7/4 receptors also contribute to eATP re-
lease by chondrocytes. Whether these receptors contain
a large pore capable of transporting ATP or regulate
such a pore is not clear. Our data suggest that, in chon-
drocytes, a P2X7/4-dependent pore releases PGE2 as
well as ATP. The lack of effectiveness of the more spe-
cific P2X7 inhibitors supports a role for P2X4 in this
process, which is further demonstrated by the effect of iver-
mectin, a relatively specific stimulant of P2X4 receptor-
mediated actions. Because reducing levels of P2X4 or P2X7
alone had no effect on eATP efflux, we hypothesize that
either P2X4 and/or P2X7 can participate in eATP trans-
port. The redundancy of this system may attest to the im-
portance of eATP efflux in cartilage.
In some cell types, pannexin-1 hemichannels may be
activated in response to P2X7 receptor stimulation, and
these serve as the conduit for ATP release. However, the
ability of P2X7 receptors to facilitate non-selective pore
formation is similar in macrophages from wild-type or
pannexin-1 knockout mice [47]. In other cell types in
which P2X7 receptors participate in eATP release, hemi-
channel inhibitors behave anomalously [16], and this
may be the case in chondrocytes. Our findings differ
from those of Garcia and Knight who showed that flufe-
namic acid reduced eATP release in bovine chondro-
cytes [12]. Variations in mechanisms among different
species, effects of culture conditions and differences in
ages of the animals may explain these differences. In a
mouse growth-plate chondrocytic cell line, Iwamoto et al.
showed an important role for pannexin-3 in eATP efflux
[48]. Certainly, growth-plate chondrocytes differ from pri-
mary articular chondrocytes in many ways. Despite the
use of a number of hemichannel inhibitors in a wide range
of concentrations, however, we could not demonstrate a
clear role for pannexins or connexins in our system.
These studies are not without limitations. Culture
models may not fully reproduce the environment that
chondrocytes see in situ. However, our cells retain all
the phenotypic features of highly differentiated chondro-
cytes [49], and we showed similar behavior in regards to
eATP efflux in chondrocytes embedded in an agarose
construct. While membrane injury resulting from cell
swelling may result in non-specific leakage of cell con-
tents including ATP from the cell, the lack of evidence
of toxicity and the specificity of the inhibitor effectsmakes this highly unlikely. The natural environment of
healthy articular chondrocytes is hyperosmolar, and time
may be necessary for chondrocytes to adjust to the lower
osmolar milieu of culture media [27]. While we allowed
cells to acclimatize for 24 hours before these experi-
ments were undertaken, differences in absolute or rela-
tive osmolarity may exist between tissue culture models
and conditions in vivo. We used a brief osmotic stress to
elicit eATP efflux and further work will be necessary to
explore the long-term effects of various osmotic states
on eATP efflux. Last, we were unable to conclusively
prove a role for P2X7/4 receptors using silencer technol-
ogy. Ultimately, studies with mice deficient in one of
more of these proteins may be necessary to demonstrate
a role for these proteins in chondrocyte ATP efflux. We
attempted to minimize concerns about off-target effects
of pharmacologic inhibitors by carefully examining tox-
icity of these agents, as well as testing their actions on
other factors impacting eATP levels.
Conclusion
In summary, we show here that ANK has a central role
in eATP release by mature articular chondrocytes, and
P2X7/4 receptors may also participate in this process.
As eATP has numerous catabolic effects in cartilage and
contributes to calcium crystal arthritis, further progress
in understanding mechanisms and identifying modula-
tors of ATP release may result in additional therapies for
common degenerative diseases of cartilage.
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